Levy Wealth Management Group LLC Sells 122 Shares of Merck & Co., Inc. (NYSE:MRK)

Levy Wealth Management Group LLC lessened its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,444 shares of the company’s stock after selling 122 shares during the quarter. Merck & Co., Inc. comprises 0.5% of Levy Wealth Management Group LLC’s holdings, making the stock its 26th biggest position. Levy Wealth Management Group LLC’s holdings in Merck & Co., Inc. were worth $1,684,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the company. Ascent Wealth Partners LLC raised its stake in Merck & Co., Inc. by 0.5% in the 4th quarter. Ascent Wealth Partners LLC now owns 16,579 shares of the company’s stock valued at $1,807,000 after purchasing an additional 89 shares during the last quarter. Creative Financial Designs Inc. ADV increased its position in Merck & Co., Inc. by 1.9% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 4,811 shares of the company’s stock worth $524,000 after purchasing an additional 92 shares in the last quarter. Bell Bank increased its position in Merck & Co., Inc. by 1.0% during the 4th quarter. Bell Bank now owns 9,235 shares of the company’s stock worth $1,007,000 after purchasing an additional 92 shares in the last quarter. Prosperity Financial Group Inc. boosted its holdings in Merck & Co., Inc. by 2.9% in the 2nd quarter. Prosperity Financial Group Inc. now owns 3,365 shares of the company’s stock worth $388,000 after acquiring an additional 95 shares during the period. Finally, Bath Savings Trust Co boosted its stake in shares of Merck & Co., Inc. by 1.8% during the 4th quarter. Bath Savings Trust Co now owns 5,539 shares of the company’s stock valued at $604,000 after buying an additional 98 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Insider Activity

In other Merck & Co., Inc. news, EVP Steven Mizell sold 50,694 shares of the company’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the sale, the executive vice president now directly owns 23,619 shares in the company, valued at $2,991,346.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Steven Mizell sold 50,694 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now owns 23,619 shares in the company, valued at $2,991,346.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the sale, the insider now owns 19,569 shares in the company, valued at approximately $2,443,972.41. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by company insiders.

Merck & Co., Inc. Stock Performance

MRK traded up $1.19 on Wednesday, hitting $131.54. The company had a trading volume of 1,574,295 shares, compared to its average volume of 8,600,913. The company’s fifty day moving average price is $125.45 and its 200 day moving average price is $113.20. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year high of $133.10. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.25 and a quick ratio of 1.00. The stock has a market cap of $333.14 billion, a price-to-earnings ratio of 931.07, a price-to-earnings-growth ratio of 0.52 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The company had revenue of $14.63 billion during the quarter, compared to analyst estimates of $14.49 billion. During the same period in the previous year, the company earned $1.62 earnings per share. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Equities analysts predict that Merck & Co., Inc. will post 8.59 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.34%. The ex-dividend date is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio is presently 2,200.00%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on MRK shares. TheStreet cut Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. Truist Financial reaffirmed a “buy” rating and issued a $142.00 target price (up from $139.00) on shares of Merck & Co., Inc. in a research report on Thursday, March 28th. Barclays raised their price target on Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. UBS Group raised their target price on Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. Finally, TD Cowen raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their target price for the company from $125.00 to $135.00 in a research note on Thursday, January 4th. One analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $129.71.

View Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.